This company listing is no longer active
673 Stock Overview
A clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Cerevel Therapeutics Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$23.60 |
| 52 Week High | US$31.80 |
| 52 Week Low | US$20.60 |
| Beta | 1.55 |
| 1 Month Change | 0% |
| 3 Month Change | 0.85% |
| 1 Year Change | -6.35% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -12.46% |
Recent News & Updates
Recent updates
Shareholder Returns
| 673 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.4% | 1.9% |
| 1Y | -6.3% | -6.5% | 14.1% |
Return vs Industry: 673 exceeded the German Biotechs industry which returned -22.5% over the past year.
Return vs Market: 673 underperformed the German Market which returned 1% over the past year.
Price Volatility
| 673 volatility | |
|---|---|
| 673 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 673 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 673's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 334 | Ron Renaud | www.cerevel.com |
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company’s products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson’s disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder.
Cerevel Therapeutics Holdings, Inc. Fundamentals Summary
| 673 fundamental statistics | |
|---|---|
| Market cap | €6.88b |
| Earnings (TTM) | -€399.43m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-17.2x
P/E RatioIs 673 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 673 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$432.84m |
| Earnings | -US$432.84m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.38 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 66.7% |
How did 673 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/03/02 17:45 |
| End of Day Share Price | 2023/12/04 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cerevel Therapeutics Holdings, Inc. is covered by 16 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Caroline Palomeque | Berenberg |
| Esther Lannie Hong | Berenberg |
| Tazeen Ahmad | BofA Global Research |